We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





Bayer Highlights Radiology Portfolio and Innovation in AI at RSNA 2022

By MedImaging International staff writers
Posted on 27 Nov 2022
Print article
Image: MEDRAD Centargo - The next big step in CT injector technology (Photo courtesy of Bayer)
Image: MEDRAD Centargo - The next big step in CT injector technology (Photo courtesy of Bayer)

Bayer (Leverkusen, Germany) is presenting new early clinical data for gadoquatrane, the company’s novel macrocyclic gadolinium-based compound currently in Phase II development, at the Radiological Society of North America (RSNA) Annual Meeting taking place from November 27 to December 1 in Chicago, USA.

Bayer is moving ahead with the advancement of its comprehensive radiology portfolio with progress on the development pipeline of new contrast agents as well as further partnerships in its digital business. In addition, Bayer has announced three collaboration agreements for its digital platform Calantic Digital Solutions as well as an AI accelerator program, reflecting the company’s commitment to driving innovations that benefit patients and their physicians, including leveraging the vast potential of artificial intelligence (AI).

Bayer is making progress with its portfolio of contrast agents and injectors. The US submission of the MEDRAD Centargo CT Injection System, the latest addition to Bayer’s computed tomography portfolio designed to simplify radiology workflows, is underway. In the area of contrast agents, gadoquatrane, Bayer’s novel macrocyclic gadolinium-based compound in Phase II, is progressing in development. New early clinical data for gadoquatrane are being presented at this year’s RSNA. Gadoquatrane features high stability as well as high relaxivity, which is a key property for use in contrast-enhanced magnetic resonance imaging, with the potential to enable a substantially lower gadolinium dose. The present study investigated its pharmacokinetics including excretion pathways, safety and tolerability in healthy volunteers.

On the occasion of RSNA 2022, Bayer also announced that it will partner with app developers Quantib, ClariPi, and EXINI Diagnostics to strategically expand the offering on its medical imaging platform Calantic Digital Solutions. The platform, which was launched recently, delivers access to applications, including those enabled by AI, for medical imaging. With these new collaboration agreements, Bayer is broadening the already available options for thoracic and neurological diseases on the platform by including tools which aim to aid in breast and prostate imaging. With cancer and cardiovascular diseases on the rise, the demand for medical imaging to detect diseases, guide treatment decisions, and aid in therapy planning is growing. AI comes with the value proposition to support diagnosis and increase the throughput of medical imaging examinations.

In addition, Bayer has recently launched Calantic SPARK, a new accelerator program for medical imaging app developers to further foster innovation in radiology AI. The program will initially focus on North America and Europe and is planned to be expanded to other regions including Asia-Pacific. Bayer offers a targeted program to accelerate market readiness for early- and late-stage projects and offerings, providing advice spanning medical, regulatory, reimbursement expertise, and market access. Tapping the thriving start-up ecosystem of AI in medical imaging, Calantic SPARK provides program participants with a potential pathway towards commercialization and distribution through Calantic Digital Solutions. Details about Calantic SPARK are being presented at Bayer’s booth as well as the AI Showcase Theatre at the RSNA.

Related Links:
Bayer

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Catheter Connector Cover
ACUSON AcuNav
New
FMT Radiographic Suite
AdvantagePlus ML1
New
High-Resolution 3D Imaging Technology
Clarity HD+ Imaging Technology

Print article
Radcal

Channels

MRI

view channel
Image: The artificial intelligence model outperformed clinical tests at predicting the progress of Alzheimer’s disease (Photo courtesy of 123RF)

AI Outperforms Clinical Tests at Predicting Alzheimer’s Progress from MRI Scans

Dementia is a major global health challenge, impacting over 55 million individuals worldwide and costing approximately USD 820 billion annually. Projections indicate that the number of cases will nearly... Read more

Ultrasound

view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

General/Advanced Imaging

view channel
Image: The NeuroLF ultra-compact brain Positron Emission Tomography (PET) scanner (Photo courtesy of Positrigo)

Breakthrough Brain PET System Aids Diagnosis of Neurological Disorders

Alzheimer's disease (AD) is the most prevalent type of dementia, representing approximately 70% of all dementia cases in individuals over 60 years of age. As of 2020, there were more than 55 million people... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Calantic Digital Solutions is an orchestrated suite of AI radiology solutions that aims to transform radiology (Photo courtesy of Bayer)

Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions

Imaging data constitutes approximately 90% of all medical data, with the volume of such data continuously expanding, thereby significantly increasing the workload for radiologists amid existing resource limitations.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.